Objective: The production of insulin-like growth factor binding protein-3 (
IGFBP-3), the main IGF-I binding protein, is regulated by GH, and its serum
levels are increased in acromegaly, We investigated its potential value as
a parameter of acromegaly activity or remission in comparison with IGF-I,
taking GH supression below 2 mu g/l after glucose load as the normal standa
rd.
Methods: Data from 40 acromegalic patients (12 males and 28 females, aged 2
8 to 79 years) were obtained retrospectively from stored samples. From thes
e, 145 pairs of IGF-I/IGFBP-3 values were collected: in 67 of them, simulta
neous measurement of GH after glucose loading allowed their classification
as active or inactive acromegaly. Relationships between IGF-I, IGFBP-3 and
GH after glucose load were assessed, as well as differences between IGF-I a
nd IGFBP-3 levels in active and inactive acromegaly,
Results: Significant positive correlation between IGF-I and IGFBP-3 in 145
samples was observed (r=0.49, P<0.0001). As for the 67 samples in which act
ivity or remission could be defined in terms of GH after glucose load, 50 w
ere active and 17 inactive. Both IGF-I and IGFBP-3 significantly correlated
with minimum GH (r=0.53, P<0.0001 and r=0.41, P<0.001 respectively), For b
oth parameters, significant differences of means between active and inactiv
e cases were observed (623+/-296 vs 300+/-108 ng/ml, P<0.0001 for IGF-I, an
d 4.1+/-1.3 vs 3.2+/-0.9 mu g/ml, P<0.006 for IGFBP-3). Yet, when comparing
in individual cases their classification as active or inactive with the fi
nding of normal or increased IGF-I and IGFBP-3, among active cases 16%; app
eared as normal according to IGF-I, and 50%; appeared as normal in terms of
IGFBP-3. Among inactive cases, 23.5% appeared as active according to IGF-I
, while 17.5% appeared as active in terms of IGFBP-3.
Conclusion: Even though IGFBP-3 reflects GH secretion, it offers no advanta
ge over IGF-I in the assessment of acromegaly, and it mag underestimate dis
ease activity in acromegalic patients.